FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance
What happened
The Molecular and Clinical Genetics Panel is weighing the Galleri test's clinical evidence today; Medicare coverage could follow FDA approval
Summary assembled by rule from the sources below